HQY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Healthequity Inc (HQY) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, growth in HSA accounts and assets, and its position in a growing market outweigh the recent valuation compression and hedge fund selling. The technical indicators suggest a positive trend, and the options data does not indicate significant bearish sentiment.
The MACD histogram is positive and expanding (0.953), indicating bullish momentum. RSI is neutral at 60.393, showing no overbought or oversold conditions. The stock is trading near its pivot level (78.692) with resistance at 82.55 and support at 74.834, suggesting a potential upward move. Moving averages are converging, indicating a possible trend continuation.
Strong Q3 financial performance with revenue up 7.23% YoY, net income up 806.40% YoY, and EPS up 883.33% YoY.
Growth in HSA accounts (6.9% YoY) and assets (13.6% YoY).
Analysts maintain positive ratings (Buy/Overweight) despite price target reductions, citing the company's defensive nature and growth potential.
No significant insider selling or political trading activity.
Hedge funds have significantly increased selling activity (213.73% increase in the last quarter).
Valuation compression across the peer group due to AI-related concerns.
Goldman Sachs downgraded the stock to Sell, citing pressure on valuation multiples.
In Q3 2026, Healthequity reported strong financials: Revenue increased to $322.16M (up 7.23% YoY), Net Income surged to $51.69M (up 806.40% YoY), EPS rose to $0.59 (up 883.33% YoY), and Gross Margin improved to 62.41% (up 11.17% YoY). These metrics indicate robust growth and operational efficiency.
Analysts have lowered price targets recently, reflecting valuation compression in the sector, but maintain positive ratings (Buy/Overweight). KeyBanc raised its price target to $125, while Jefferies, Barclays, and BTIG emphasize the company's growth potential and defensive nature in the healthcare and tech sectors. Goldman Sachs downgraded the stock to Sell, citing valuation concerns.
